share_log

Maxim Group Maintains Buy on Actinium Pharma, Raises Price Target to $30

Benzinga ·  Mar 19 12:59

Maxim Group analyst Jason McCarthy maintains Actinium Pharma (AMEX:ATNM) with a Buy and raises the price target from $20 to $30.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment